Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Mar. 31, 2020 | May 18, 2020 | |
Document And Entity Information | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2020 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2020 | |
Current Fiscal Year End Date | --09-30 | |
Entity File Number | 000-56090 | |
Entity Registrant Name | Pharmagreen Biotech Inc. | |
Entity Central Index Key | 0001435181 | |
Entity Tax Identification Number | 98-0491567 | |
Entity Incorporation, State or Country Code | NV | |
Entity Address, Address Line One | 2987 Blackbear Court | |
Entity Address, Address Line Two | Coquitlam | |
Entity Address, State or Province | BC | |
Entity Address, Postal Zip Code | V3E 3A2 | |
City Area Code | 702 | |
Local Phone Number | 803-9404 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | No | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Elected Not To Use the Extended Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 83,145,003 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2020 | Sep. 30, 2019 |
Current assets | ||
Cash | $ 37,105 | $ 62,682 |
Amounts receivable | 899 | 10,639 |
Prepaid expenses and deposits | 355,071 | 115,856 |
Total current assets | 393,075 | 189,177 |
Property, plant, and equipment | 411,425 | 441,095 |
Total assets | 804,500 | 630,272 |
Current liabilities | ||
Accounts payable and accrued liabilities | 549,387 | 855,766 |
Advance from Alliance Growers Corp. | 52,824 | 56,634 |
Due to related parties | 351,038 | 475,666 |
Promissory note | 40,000 | |
Convertible notes - current portion, net of unamortized discount of $566,191 and $2,895, respectively | 134,709 | 75,105 |
Derivative liability | 678,104 | |
Total current liabilities | 1,806,062 | 1,463,171 |
Convertible notes, net of unamortized discount of $26,504 and $27,321, respectively | 2,417 | 1,599 |
Total liabilities | 1,808,479 | 1,464,770 |
Stockholders' deficit | ||
Common stock Authorized: 500,000,000 shares, $0.001 par value; 75,724,899 and 75,646,835 shares issued and outstanding, respectively | 75,725 | 75,647 |
Additional paid-in capital | 3,793,780 | 3,772,781 |
Accumulated other comprehensive income (loss) | 66,950 | 47,824 |
Deficit | (4,939,007) | (4,729,476) |
Total Pharmagreen Biotech Inc. stockholders' deficit | (1,002,552) | (833,224) |
Non-controlling interest | (1,427) | (1,274) |
Total stockholders' deficit | (1,003,979) | (834,498) |
Total liabilities and stockholders' deficit | $ 804,500 | $ 630,272 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) | Mar. 31, 2020 | Sep. 30, 2019 |
Statement of Financial Position [Abstract] | ||
Convertible Notes, Unamortized Discount, Current | $ 566,191 | $ 2,895 |
Convertible Notes, Unamortized Discount, Noncurrent | $ 26,504 | $ 27,321 |
Common Stock, Par Value | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 500,000,000 | 500,000,000 |
Common Stock, Shares Issued | 75,724,899 | 75,646,835 |
Common Stock, Shares Outstanding | 75,724,899 | 75,646,835 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) | 3 Months Ended | 6 Months Ended | ||||
Mar. 31, 2020USD ($)shares | Mar. 31, 2020$ / shares | Mar. 31, 2019USD ($)shares | Mar. 31, 2019$ / shares | Mar. 31, 2020USD ($)$ / sharesshares | Mar. 31, 2019USD ($)$ / sharesshares | |
Expenses | ||||||
Consulting fees | $ 53,075 | $ 46,806 | $ 123,891 | $ 102,308 | ||
Foreign exchange loss | 31,596 | (7,992) | 21,849 | 35,195 | ||
General and administrative | 37,186 | 23,488 | 62,082 | 50,758 | ||
License application fees | (7) | (7) | 902 | 1,925 | ||
Professional fees | 24,217 | 19,805 | 49,847 | 63,365 | ||
Research and development (recovery) | 6,888 | 36,604 | ||||
Salaries and wages | 4,535 | 4,579 | 9,147 | 8,749 | ||
Total expenses | 150,602 | 93,567 | 267,718 | 298,904 | ||
Net loss before other income (expense) | (150,602) | (93,567) | (267,718) | (298,904) | ||
Other income (expense) | ||||||
Accretion of discount on convertible notes | (16,366) | (298) | (23,012) | (659) | ||
Finance costs | (45,000) | (187,245) | ||||
Loss on disposal of the net assets of Canna Companion Products, Inc. | (122,703) | (159,998) | ||||
Loss on settlement on convertible notes | (6,513) | (6,513) | ||||
Write-off of accounts payable | 292,557 | 292,557 | ||||
Total other income (expense) | 146,975 | (298) | 58,034 | (187,904) | ||
Net loss | (3,627) | (93,865) | (209,684) | (486,808) | ||
Less: net loss attributable to non-controlling interest | 117 | 782 | 153 | 782 | ||
Net loss attributable to Pharmagreen Biotech Inc. | (3,510) | (93,083) | (209,531) | (486,026) | ||
Comprehensive income (loss) | ||||||
Foreign currency translation gain (loss) | 31,525 | (46,067) | 19,126 | 52,703 | ||
Comprehensive loss | $ 28,015 | $ (139,150) | $ (190,405) | $ (433,323) | ||
Basic and diluted loss per share | (per share) | $ (0.01) | |||||
Weighted average number of shares outstanding | shares | 75,652,840 | 74,316,289 | 75,649,821 | 73,235,221 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) | Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Income (Loss) | Deficit | Noncontrolling Interest | Total |
Beginning Balance at Sep. 30, 2018 | $ 71,620 | $ 2,464,136 | $ 38,722 | $ (3,961,939) | $ (1,387,461) | |
Beginning Balance (in Shares) at Sep. 30, 2018 | 71,620,100 | |||||
Issuance of common stock pursuant to the conversion of convertible notes | $ 2,000 | (1,800) | 200 | |||
Issuance of common stock pursuant to the conversion of convertible notes (in Shares) | 2,000,000 | |||||
Issuance of common stock for financing services | $ 52 | 187,193 | 187,245 | |||
Issuance of common stock for financing services (in Shares) | 51,725 | |||||
Foreign currency translation gain | 98,770 | 98,770 | ||||
Net loss for the period | (392,943) | (392,943) | ||||
Ending Balance at Dec. 31, 2018 | $ 73,672 | 2,649,529 | 137,492 | (4,354,882) | (1,494,189) | |
Ending Balance (in Shares) at Dec. 31, 2018 | 73,671,825 | |||||
Beginning Balance at Sep. 30, 2018 | $ 71,620 | 2,464,136 | 38,722 | (3,961,939) | (1,387,461) | |
Beginning Balance (in Shares) at Sep. 30, 2018 | 71,620,100 | |||||
Issuance of common stock pursuant to the conversion of convertible notes | 300 | |||||
Issuance of common stock for financing services | 187,245 | |||||
Issuance of common stock of 1155097 BC Ltd. | 1,018,229 | |||||
Foreign currency translation gain | 52,703 | |||||
Net loss for the period | (486,808) | |||||
Ending Balance at Mar. 31, 2019 | $ 74,672 | 3,666,857 | 91,425 | (4,447,965) | (782) | (615,793) |
Ending Balance (in Shares) at Mar. 31, 2019 | 74,671,825 | |||||
Beginning Balance at Dec. 31, 2018 | $ 73,672 | 2,649,529 | 137,492 | (4,354,882) | (1,494,189) | |
Beginning Balance (in Shares) at Dec. 31, 2018 | 73,671,825 | |||||
Issuance of common stock pursuant to the conversion of convertible notes | $ 1,000 | (900) | 100 | |||
Issuance of common stock pursuant to the conversion of convertible notes (in Shares) | 1,000,000 | |||||
Issuance of common stock of 1155097 BC Ltd. | 1,018,228 | 1,018,228 | ||||
Foreign currency translation gain | (46,067) | (46,067) | ||||
Net loss for the period | (93,083) | (782) | (93,865) | |||
Ending Balance at Mar. 31, 2019 | $ 74,672 | 3,666,857 | 91,425 | (4,447,965) | (782) | (615,793) |
Ending Balance (in Shares) at Mar. 31, 2019 | 74,671,825 | |||||
Beginning Balance at Sep. 30, 2019 | $ 75,647 | 3,772,781 | 47,824 | (4,729,476) | (1,274) | (834,498) |
Beginning Balance (in Shares) at Sep. 30, 2019 | 75,646,835 | |||||
Foreign currency translation gain | (12,399) | (12,399) | ||||
Net loss for the period | (206,021) | (36) | (206,057) | |||
Ending Balance at Dec. 31, 2019 | $ 75,647 | 3,772,781 | 35,425 | (4,935,497) | (1,310) | (1,052,954) |
Ending Balance (in Shares) at Dec. 31, 2019 | 75,646,835 | |||||
Beginning Balance at Sep. 30, 2019 | $ 75,647 | 3,772,781 | 47,824 | (4,729,476) | (1,274) | (834,498) |
Beginning Balance (in Shares) at Sep. 30, 2019 | 75,646,835 | |||||
Issuance of common stock pursuant to the conversion of convertible notes | 78 | |||||
Issuance of common stock for financing services | ||||||
Issuance of common stock of 1155097 BC Ltd. | ||||||
Foreign currency translation gain | 19,126 | |||||
Net loss for the period | (209,684) | |||||
Ending Balance at Mar. 31, 2020 | $ 75,725 | 3,793,780 | 66,950 | (4,939,007) | (1,427) | (1,003,979) |
Ending Balance (in Shares) at Mar. 31, 2020 | 75,724,899 | |||||
Beginning Balance at Dec. 31, 2019 | $ 75,647 | 3,772,781 | 35,425 | (4,935,497) | (1,310) | (1,052,954) |
Beginning Balance (in Shares) at Dec. 31, 2019 | 75,646,835 | |||||
Issuance of common stock pursuant to the conversion of convertible notes | $ 78 | 20,999 | 21,077 | |||
Issuance of common stock pursuant to the conversion of convertible notes (in Shares) | 78,064 | |||||
Foreign currency translation gain | 31,525 | 31,525 | ||||
Net loss for the period | (3,510) | (117) | (3,627) | |||
Ending Balance at Mar. 31, 2020 | $ 75,725 | $ 3,793,780 | $ 66,950 | $ (4,939,007) | $ (1,427) | $ (1,003,979) |
Ending Balance (in Shares) at Mar. 31, 2020 | 75,724,899 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
OPERATING ACTIVITIES | ||
Net loss | $ (209,684) | $ (486,808) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Accretion of discount on convertible notes | 23,012 | 659 |
Financing fees | 45,000 | |
Loss on change in fair value of derivative liability | 159,998 | |
Loss on settlement of convertible note | 6,513 | |
Shares issued for services | 187,245 | |
Write-off of accounts payable | (292,557) | |
Changes in non-cash operating working capital | ||
Accounts receivable and other receivables | 9,740 | (4,341) |
Prepaid expenses and deposits | (239,215) | 474 |
Accounts payable and accrued liabilities | 27,340 | 40,769 |
Due to related parties | (4,352) | (42,391) |
Net cash used in operating activities | (474,205) | (304,393) |
INVESTING ACTIVITIES | ||
Acquisition of property and equipment | (31,382) | |
Net cash used in investing activities | (31,382) | |
FINANCING ACTIVITIES | ||
Proceeds from the issuance of convertible notes | 570,080 | |
Proceeds from advances from Alliance Growers Corp. | 170,032 | |
Repayment of loans from related parties | (120,276) | |
Financing costs paid | (5,000) | |
Net cash provided by financing activities | 444,804 | 170,032 |
Effect of foreign exchange rate changes on cash | 3,824 | 23,267 |
Increase in cash | (25,577) | (142,476) |
Cash, beginning of year | 62,682 | 151,869 |
Cash, end of year | 37,105 | 9,393 |
Non-cash investing and financing activities: | ||
Original issue discount on convertible notes | 532,594 | |
Issuance of common stock pursuant to the conversion of convertible notes | 78 | 300 |
Issuance of equity in 1155097 B.C. Ltd in exchange for advances payable | 1,018,229 | |
Issuance of promissory note as a financing fee | 40,000 | |
Supplemental disclosures: | ||
Interest paid | ||
Income taxes paid |
Nature of Business and Continua
Nature of Business and Continuance of Operations | 6 Months Ended |
Mar. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of Business and Continuance of Operations | 1. Nature of Business and Continuance of Operations Pharmagreen Biotech Inc. (“the Company”) was incorporated under the laws of the State of Nevada, U.S. on November 26, 2007, under the name Azure International, Inc. On October 30, 2008, and effective as of the same date, the Company filed Articles of Merger (“Articles”) with the Secretary of State of the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation and Azure International, Inc. As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc. The Company was previously in the business of providing technical advisory and appraisals to the aircraft and aviation business as well as providing sourcing for aircraft leases and parts. Pursuant to a Share Exchange Agreement with WFS Pharmagreen Inc. (“WFS”) on May 2, 2018, the Company changed its name to Pharmagreen Biotech Inc. and changed its principal business to the construction of a biotech complex in Deroche, British Columbia, Canada, for the purpose of producing a variety of starter plantlets for the Canadian and international high CBD hemp and medical cannabis industries through the application of the proprietary plant tissue culture in vitro process called “Chibafreen”. This proprietary process will produce plantlets that will be genetically identical and free of pests and disease free with consistent and certifiable constituent properties. Going Concern These condensed consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at March 31, 2020, the Company has not earned any revenues from operations, has a working capital deficit of $1,412,987, and has an accumulated deficit of $4,939,007. During the six months ended March 31, 2020, the Company incurred a net loss of $209,684 and used cash flows for operations of $474,205. These factors raise substantial doubt upon the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern. The recent outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies, disruptions of financial markets, and created uncertainty regarding potential impacts to the Company’s supply chain, operations, and customer demand. The COVID-19 pandemic has impacted and could further impact the Company’s operations and the operations of the Company’s suppliers and vendors as a result of quarantines, facility closures, and travel and logistics restrictions. The extent to which the COVID-19 pandemic impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on the Company’s customers, suppliers, and vendors and the remedial actions and stimulus measures adopted by local and federal governments, and to what extent normal economic and operating conditions can resume. The management team is closely following the progression of COVID-19 and its potential impact on the Company. Even after the COVID-19 pandemic has subsided, the Company may experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time our business, liquidity, capital resources and financial results. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Significant Accounting Policies (a) Interim Financial Statements These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. (b) Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 BC Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30. (c) Use of Estimates and Judgments The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the allowance for doubtful accounts, the recoverability of property and equipment, the equity component of convertible notes, fair value of derivative liabilities, fair value of stock-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. (d) Loss Per Share The Company computes loss per share in accordance with ASC 260, " Earnings per Share (e) Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The standard became effective for the Company in the first quarter of fiscal year 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. In February 2016, Topic 842, Leases Leases The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. |
Property and Equipment
Property and Equipment | 6 Months Ended |
Mar. 31, 2020 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment | 3. Property and Equipment Cost Accumulated depreciation Net carrying Net carrying Construction in progress 411,425 — 411,425 441,095 As at March 31, 2020, and September 30, 2019, costs related to the construction of cannabis production complex were capitalized as construction in progress and not depreciated. Depreciation will commence when construction is completed, and the facility is available for its intended use. |
Accounts Payable and Accrued Li
Accounts Payable and Accrued Liabilities | 6 Months Ended |
Mar. 31, 2020 | |
Payables and Accruals [Abstract] | |
Accounts Payable and Accrued Liabilities | 4. Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consists of the following: March 31, September 30, Accounts payable 502,964 829,942 Accrued interest payable 46,423 25,824 549,387 855,766 During the six months ended March 31, 2020, the Company recognized a write-off of accounts payable of $292,557 (2019 - $nil) related to professional fees that are no longer owing. |
Promissory Note
Promissory Note | 6 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Promissory Note | 5. Promissory Note On November 22, 2019, the Company entered into a promissory note with an unrelated party for $40,000 in connection with an equity purchase agreement (Refer to Note 10(b)). The promissory note is unsecured, due on November 30, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum. During the period ended March 31, 2020, the Company recognized accrued interest of $995 (2019 - $426). |
Convertible Notes
Convertible Notes | 6 Months Ended |
Mar. 31, 2020 | |
Debt Disclosure [Abstract] | |
Convertible Notes | 6. Convertible Notes (a) On April 4, 2018, the amount of $32,485 owed to related parties was converted to Series A convertible notes, which are unsecured, non-interest bearing, and due on April 4, 2023. These notes are convertible in whole or in part, at any time until maturity, to common shares of the Company at $0.0001 per share. The outstanding balance remaining at maturity shall bear interest at 12% per annum until fully paid. The Company evaluated the convertible notes for a beneficial conversion feature in accordance with ASC 470-20 Debt with Conversion and Other Options During the year ended September 30, 2018, the Company issued 31,745,000 shares of common stock upon the conversion of $3,175 of Series A convertible notes, which included 18,000,000 common shares to the President of the Company and 5,320,000 common shares to family members of the President of the Company. Upon conversion, the Company immediately recognized the related remaining debt discount of $3,112 as accretion expense. During the year ended September 30, 2019, the Company issued 3,900,000 shares of common stock upon the conversion of $390 of Series A convertible notes. Upon conversion, the Company immediately recognized the related remaining debt discount of $375 as accretion expense. As at March 31, 2020, the carrying value of the convertible notes was $2,417 (September 30, 2019 - $1,599) and had an unamortized discount of $26,504 (September 30, 2019 - $27,321). During the six months ended March 31, 2020, the Company recorded accretion expense of $812 (2019 - $659). (b) On September 17, 2019, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,000 was paid directly to third parties for financing costs, resulting in cash proceeds to the Company of $75,000. The note is due on September 20, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. Due to this provision, the Company considered whether the embedded conversion option qualifies for derivative accounting under ASC 815-15 Derivatives and Hedging The convertible note became convertible on March 15, 2020. The Company evaluated the convertible note for a beneficial conversion feature in accordance with ASC 470-20 Debt with Conversion and Other Options During the six months ended March 31, 2020, the Company issued 78,064 shares of common stock upon the conversion of $10,000 of the convertible note. Upon conversion, the Company immediately recognized the related remaining debt discount of $9,924 as accretion expense. The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the six months ended March 31, 2020, the Company recognized accretion expense of $1,845 (2019 - $nil). As at March 31, 2020, the carrying value of the convertible note was $854 (September 30, 2019 - $75,105), net of an unamortized discount of $77,146 (September 30, 2019 - $2,895). (c) On October 1, 2019, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,255 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $74,745. The note is due on October 1, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period prior to the issuance date; or (ii) 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the six months ended March 31, 2020, the Company recognized accretion expense of $12,281. As at March 31, 2020, the carrying value of the convertible note was $12,781, net of an unamortized discount of $65,219. (d) On October 17, 2019, the Company entered into a convertible note with an unrelated party for $63,000, of which $3,000 was paid directly to third parties for financing costs, resulting in cash proceeds to the Company of $60,000. The note is due on October 17, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. In December 2019, the conversion price was amended to 46%. Due to this provision, the Company considered whether the embedded conversion option qualifies for derivative accounting under ASC 815-15 Derivatives and Hedging The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the six months ended March 31, 2020, the Company recognized accretion expense of $1,343. As at March 31, 2020, the carrying value of the convertible note was $61,343, net of an unamortized discount of $1,657. (e) On January 2, 2020, the Company entered into a convertible note with an unrelated party for $53,000, of which $3,000 was paid directly to third parties for financing costs, resulting in cash proceeds to the Company of $50,000. The note is due on January 2, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. Due to this provision, the Company considered whether the embedded conversion option qualifies for derivative accounting under ASC 815-15 Derivatives and Hedging The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the six months ended March 31, 2020, the Company recognized accretion expense of $714. As at March 31, 2020, the carrying value of the convertible note was $50,714, net of an unamortized discount of $2,286. (f) On January 14, 2020, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,000 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $75,000. The note is due on January 14, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 15% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) 65% of the lowest trading price during the 20-trading day period prior to the issuance date; or (ii) 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the six months ended March 31, 2020, the Company recognized accretion expense of $1,778. As at March 31, 2020, the carrying value of the convertible note was $2,278, net of an unamortized discount of $75,722. (g) On January 15, 2020, the Company entered into a convertible note with an unrelated party for $61,000, of which $7,400 was paid directly to third parties for financing costs. The convertible note has a purchase price of $58,000, with an original issue discount of $3,000, resulting in proceeds to the Company of $50,600. The note is due on January 15, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the six months ended March 31, 2020, the Company recognized accretion expense of $903. As at March 31, 2020, the carrying value of the convertible note was $1,403, net of an unamortized discount of $59,597. (h) On January 15, 2020, the Company entered into a convertible note with an unrelated party for $55,000, of which $2,500 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $52,500. The note is due on January 15, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 65% of the lowest trading price during the 20 consecutive trading day period on which at least 100 shares of common stock were traded prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the six months ended March 31, 2020, the Company recognized accretion expense of $871. As at March 31, 2020, the carrying value of the convertible note was $1,371, net of an unamortized discount of $53,629. (i) On January 21, 2020, the Company entered into a convertible note with an unrelated party for $66,150, of which $7,800 was paid directly to third parties for financing costs. The convertible note has a purchase price of $63,000, with an original issue discount of $3,150, resulting in proceeds to the Company of $55,200. The note is due on January 21, 2021, and bears interest on the unpaid principal balance at a rate of 8% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 60% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the six months ended March 31, 2020, the Company recognized accretion expense of $840. As at March 31, 2020, the carrying value of the convertible note was $1,340, net of an unamortized discount of $64,810. (j) On January 22, 2020, the Company entered into a convertible note with an unrelated party for $78,750, of which $9,750 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $69,000. The note is due on January 22, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the six months ended March 31, 2020, the Company recognized accretion expense of $875. As at March 31, 2020, the carrying value of the convertible note was $1,375, net of an unamortized discount of $77,375. (k) On February 4, 2020, the Company entered into a convertible note with an unrelated party for $100,000, of which $16,970 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $83,030. The note is due on February 4, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 60% of the average of the two lowest trading prices during the 10-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the six months ended March 31, 2020, the Company recognized accretion expense of $750. As at March 31, 2020, the carrying value of the convertible note was $1,250, net of an unamortized discount of $98,750. |
Derivative Liability
Derivative Liability | 6 Months Ended |
Mar. 31, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Liability | 7. Derivative Liabilities The embedded conversion option of the Company’s convertible notes described in Note 6 contain a conversion feature that qualifies for embedded derivative classification. The fair value of this liability will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement of operations as a gain or loss on change in fair value of derivative liabilities. The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities: Balance Balance, September 30, 2019 — Addition of new derivative liabilities 630,821 Conversion of convertible notes (14,488 ) Change in fair value of embedded conversion option 61,771 Balance, March 31, 2020 678,104 The Company uses Level 3 inputs for its valuation methodology for the embedded conversion option liabilities as their fair values were determined by using a binomial model based on various assumptions. Significant changes in any of these inputs in isolation would result in a significant change in the fair value measurement. As required, these are classified based on the lowest level of input that is significant to the fair value measurement. The following table shows the assumptions used in the calculations: Expected Risk-free Expected Expected life As at date of issuance 123.84% to 192.74% 0.38% to 1.73% 0 % 0.51 to 1.00 As at March 31, 2020 164.47% to 208.15% 0.15% to 0.17% 0 % 0.46 to 0.84 |
Related Party Transactions
Related Party Transactions | 6 Months Ended |
Mar. 31, 2020 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 8. Related Party Transactions (a) As at March 31, 2020, the Company owed $299,272 (Cdn$424,904) (September 30, 2019 - $372,799 (Cdn$493,694)) to the President of the Company, which is non-interest bearing, unsecured, and due on demand. During the six months ended March 31, 2020, the Company incurred consulting fees of $48,841 (2019 - $45,288) to the President of the Company. (b) As at March 31, 2020, the Company owed $nil (September 30, 2019 - $47,367 (Cdn$62,730)) to a company controlled by the President of the Company, which is non-interest bearing, unsecured, and due on demand. (c) As at March 31, 2020, the Company owed $51,766 (Cdn$73,500) (September 30, 2019 - $55,500 (Cdn$73,500)) to the father of the President of the Company, which is non-interest bearing, unsecured, and due on demand. (d) As at March 31, 2020, the Company owed $24,087 (Cdn$34,200) (September 30, 2019 - $25,825 (Cdn$34,200)) to a Company owned by the father of the President of the Company, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand. (e) As at March 31, 2020, the Company owed $302,502 (Cdn$429,507) (September 30, 2019 – $291,504 (Cdn$386,039)) to a company controlled by the Chief Financial Officer of WFS, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand. During the six months ended March 31, 2020, the Company incurred consulting fees of $48,841 (2019 - $45,288) to the company controlled by the Chief Financial Officer of WFS. |
Common Stock
Common Stock | 6 Months Ended |
Mar. 31, 2020 | |
Equity [Abstract] | |
Common Stock | 9. Common Stock On March 24, 2020, the Company issued 78,064 shares of common stock with a fair value of $21,077 pursuant to the conversion of $10,000 of a convertible note (Note 6(b)). |
Commitment
Commitment | 6 Months Ended |
Mar. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitment | 10. Commitments (a) Effective December 11, 2017, the Company entered into a binding Letter of Intent (“LOI”) with Alliance Growers Corp. (“Alliance”), whereby the Company will build a new cannabis biotech complex located in Deroche, British Columbia, through their subsidiary, 115BC. On January 25, 2019, the Company’s wholly owned subsidiaries WFS and 115BC entered into an option agreement with Alliance, which superseded the LOI entered into on December 11, 2017. The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000. On January 25, 2019, 115BC issued 8 shares of common stock to Alliance upon exercise of the first option for consideration of $1,018,182 (Cdn$1,350,008), which was recognized as additional paid-in capital. As at March 31, 2020, the Company received advances of $52,823 (Cdn$75,000) (September 30, 2019 - $56,634 (Cdn$75,000)) from Alliance, which is unsecured, non-interest bearing, and due on demand. (b) On November 22, 2019, the Company entered into an equity purchase agreement with an unrelated party, whereby the third party is to purchase up to $10,000,000 of the Company’s common stock. The equity purchase agreement is effective for a term of 2 years from the effective date of the registration statement. The purchase price would be 85% of the market price. In return, the Company issued a promissory note of $40,000 (Refer to Note 5). In addition, the third party is required to pay an additional commitment fee of $10,000, of which $5,000 was paid upon signing the term sheet and the remaining $5,000 is due upon completion of the first tranche of the financing. |
Subsequent Events
Subsequent Events | 6 Months Ended |
Mar. 31, 2020 | |
Subsequent Events [Abstract] | |
Subsequent Events | 11. Subsequent Events (a) On April 1, 2020, the Company issued 6,000,000 shares of common stock pursuant to the conversion of $600 of a convertible note (Note 6(a)). (b) On April 2, 2020, the Company issued 136,612 shares of common stock pursuant to the conversion of $10,000 of a convertible note (Note 6(b)). (c) On April 16, 2020, the Company issued 351,288 shares of common stock pursuant to the conversion of $15,000 of a convertible note (Note 6(b)). (d) On April 30, 2020, the Company issued 423,729 shares of common stock pursuant to the conversion of $15,000 of a convertible note (Note 6(b)). (e) On May 4, 2020, the Company issued 508,475 shares of common stock pursuant to the conversion of $18,000 of a convertible note (Note 6(b)). |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Interim Financial Statements | (a) Interim Financial Statements These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. |
Basis of Presentation | (b) Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 BC Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30. |
Use of Estimates and Judgments | (c) Use of Estimates and Judgments The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the allowance for doubtful accounts, the recoverability of property and equipment, the equity component of convertible notes, fair value of derivative liabilities, fair value of stock-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. |
Loss per share | (d) Loss Per Share The Company computes loss per share in accordance with ASC 260, " Earnings per Share |
Recently Adopted Accounting Pronouncements | (e) Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The standard became effective for the Company in the first quarter of fiscal year 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. In February 2016, Topic 842, Leases Leases The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. |
Property and Equipment (Tables)
Property and Equipment (Tables) | 6 Months Ended |
Mar. 31, 2020 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and Equipment | Cost Accumulated depreciation Net carrying Net carrying Construction in progress 411,425 — 411,425 441,095 |
Accounts Payable and Accrued _2
Accounts Payable and Accrued Liabilities (Tables) | 6 Months Ended |
Mar. 31, 2020 | |
Accounts Payable And Accrued Liabilities | |
Schedule of Accounts Payable and Accrued Liabilities | Accounts payable and accrued liabilities consists of the following: March 31, September 30, Accounts payable 502,964 829,942 Accrued interest payable 46,423 25,824 549,387 855,766 |
Derivative Liability (Tables)
Derivative Liability (Tables) | 6 Months Ended |
Mar. 31, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Derivative Liability | The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities: Balance Balance, September 30, 2019 — Addition of new derivative liabilities 630,821 Conversion of convertible notes (14,488 ) Change in fair value of embedded conversion option 61,771 Balance, March 31, 2020 678,104 The following table shows the assumptions used in the calculations: Expected Risk-free Expected Expected life As at date of issuance 123.84% to 192.74% 0.38% to 1.73% 0 % 0.51 to 1.00 As at March 31, 2020 164.47% to 208.15% 0.15% to 0.17% 0 % 0.46 to 0.84 |
Nature of Business and Contin_2
Nature of Business and Continuance of Operations (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Mar. 31, 2020 | Mar. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | Sep. 30, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||
Working Capital Deficit | $ 1,412,987 | $ 1,412,987 | |||
Accumulated Deficit | 4,939,007 | 4,939,007 | $ 4,729,476 | ||
Net Loss | $ 3,510 | $ 93,083 | 209,531 | $ 486,026 | |
Net cash used in operating activities | $ 474,205 | $ 304,393 |
Significant Accounting Policies
Significant Accounting Policies (Details Narrative) - shares | 6 Months Ended | 12 Months Ended |
Mar. 31, 2020 | Sep. 30, 2019 | |
Significant Accounting Policies | ||
Potentially Dilutive Shares Outstanding | 373,968,308 | 364,850,535 |
Property and Equipment (Details
Property and Equipment (Details) - USD ($) | Mar. 31, 2020 | Sep. 30, 2019 |
Property, Plant and Equipment [Abstract] | ||
Construction in progress | $ 411,425 | $ 441,095 |
Accumulated depreciation | ||
Net Carrying Value | $ 411,425 | $ 441,095 |
Accounts Payable and Accrued _3
Accounts Payable and Accrued Liabilities (Details) - USD ($) | Mar. 31, 2020 | Sep. 30, 2019 |
Disclosure Accounts Payable And Accrued Liabilities Details Abstract | ||
Accounts payable | $ 502,964 | $ 829,942 |
Accrued interest payable | 46,423 | 25,824 |
Accounts Payable and Accrued Liabilities | $ 549,387 | $ 855,766 |
Promissory Note (Details Narrat
Promissory Note (Details Narrative) - USD ($) | 6 Months Ended | |||
Mar. 31, 2020 | Mar. 31, 2019 | Nov. 22, 2019 | Sep. 30, 2019 | |
Disclosure Promissory Note Details Narrative Abstract | ||||
Promissory Note with unrelated party | $ 40,000 | $ 40,000 | ||
Accured Interest | $ 995 | $ 426 |
Convertible Notes (Details Narr
Convertible Notes (Details Narrative) | 6 Months Ended | 12 Months Ended | ||||
Mar. 31, 2020USD ($)$ / shares | Mar. 31, 2019USD ($) | Sep. 30, 2019USD ($)$ / sharesshares | Sep. 30, 2018USD ($)shares | Apr. 04, 2018USD ($) | Apr. 04, 2018$ / shares | |
Common Stock, Par Value | $ / shares | $ 0.001 | $ 0.001 | ||||
Convertible Note [Member] | NotesIssued April 04, 2018 | ||||||
Amount Owed to Related Party | $ 32,485 | |||||
Common Stock, Par Value | $ / shares | $ .0001 | |||||
Common Stock Share Issued | shares | 3,900,000 | |||||
Accretion Expense | $ 369 | $ 361 | $ 375 | $ 3,112 | ||
Carrying Value of Convertible Notes | 1,968 | 1,599 | ||||
Unamortized Discount | $ 26,952 | $ 27,321 | ||||
Convertible Note [Member] | NotesIssued April 04, 2018 | President [Member] | ||||||
Common Stock Share Issued | shares | 31,745,000 | |||||
Convertible Note [Member] | NotesIssued April 04, 2018 | Family of President [Member] | ||||||
Common Stock Share Issued | shares | 5,320,000 |
Derivative Liability (Details)
Derivative Liability (Details) | 6 Months Ended |
Mar. 31, 2020USD ($) | |
Disclosure Derivative Liability Details Abstract | |
Derivative Liability | |
Addition of new derivative liabilities | 630,821 |
Conversion of convertible notes | (14,488) |
Change in fair value of embedded conversion option | 61,771 |
Derivative Liability | $ 678,104 |
Derivative Liability (Details 2
Derivative Liability (Details 2) - Derivative Liability [Member] | 6 Months Ended | 12 Months Ended |
Mar. 31, 2020 | Sep. 30, 2019 | |
Expected dividend yield | 0.00% | 0.00% |
Minimummember | ||
Expected volatility | 164.47% | 123.84% |
Risk-free interest rate | 0.15% | 0.38% |
Expected life | 5 months 16 days | 6 months 4 days |
Minimummember | ||
Expected volatility | 208.15% | 192.74% |
Risk-free interest rate | 0.17% | 1.73% |
Expected life | 10 months 2 days | 1 year |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) | 3 Months Ended | 6 Months Ended | |||||
Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | Mar. 31, 2020CAD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2019CAD ($) | |
Due to Related Parties | $ 351,038 | $ 351,038 | $ 475,666 | ||||
Consulting Fees | 53,075 | $ 46,806 | 123,891 | $ 102,308 | |||
President [Member] | |||||||
Due to Related Parties | 299,272 | 299,272 | 372,799 | ||||
Consulting Fees | 48,841 | 45,288 | |||||
President [Member] | CANADA | |||||||
Due to Related Parties | $ 424,904 | $ 493,694 | |||||
Company Controller By President [Member] | |||||||
Due to Related Parties | 47,367 | ||||||
Company Controller By President [Member] | CANADA | |||||||
Due to Related Parties | 62,730 | ||||||
Mother of President [Member] | |||||||
Due to Related Parties | 51,766 | 51,766 | 55,500 | ||||
Mother of President [Member] | CANADA | |||||||
Due to Related Parties | 73,500 | 73,500 | |||||
Company Controller By Chief Financial Officer [Member] | |||||||
Due to Related Parties | 302,502 | 302,502 | 291,504 | ||||
Consulting Fees | 48,841 | $ 45,288 | |||||
Company Controller By Chief Financial Officer [Member] | CANADA | |||||||
Due to Related Parties | 429,507 | 386,039 | |||||
Father of President [Member] | |||||||
Due to Related Parties | $ 24,087 | $ 24,087 | $ 25,825 | ||||
Father of President [Member] | CANADA | |||||||
Due to Related Parties | $ 34,200 | $ 34,200 |
Commitments (Details Narrative)
Commitments (Details Narrative) | Jan. 25, 2019USD ($)shares | Jan. 25, 2019CAD ($)shares | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | Dec. 31, 2018USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) |
Common Stock Issued upon exercise of the option | $ 21,077 | $ 100 | $ 200 | $ 78 | $ 300 | ||
Alliance Growers Corp. [Member] | |||||||
Common Stock Issued upon exercise of the option | $ 1,018,182 | ||||||
Common Stock Issued upon exercise of the option (in Shares) | shares | 8 | 8 | |||||
Alliance Growers Corp. [Member] | CANADA | |||||||
Common Stock Issued upon exercise of the option | $ 1,350,008 |